BIONDVAX

BIONDVAX

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Biondvax_logo

Industry:
Israeli Biopharmaceutical Company

Address:
Jerusalem BioPark, Jerusalem, Israel Zipcode 7414002

Country:
Israel

Phone:
972 8 930 2529

Market Cap:
43.30M
Total Assets:
115.75M
Total Cash:
72.47M

Number of employees: 16 (2016)


Key Executives
Name Title Pay Year Born
Dr. Ron Babecoff D.V.M., DVM Co-Founder, Pres & Sr. Advisor N/A 1962(58 years old)
Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA Chief Financial Officer N/A 1970(50 years old)
Mr. Elad Mark B.Sc., Eng., M.B.A. Chief Operating Officer N/A 1982(38 years old)
Dr. Tamar Ben Yedidia Chief Scientific Officer N/A 1964(56 years old)
Mr. Amir Reichman M.B.A., M.Sc. CEO & Director N/A N/A
Dr. Shimon Hassin Chief Admin. Officer N/A N/A
Mr. Joshua E. Phillipson B.Sc., M.B.A. Director of Bus. Devel. & Investor Relations N/A N/A



Financial & Stock
Exchange NasdaqCM. Currency in USD. Market state CLOSED
According to Biondvax's financial reports the company's revenue in 2019 were 0 an decrease(NAN%) over the years 2018 revenue that were of 0. In 2019 the company's total earnings were -109.19M while total earnings in 2018 were -87.73M( +25.29%).
Company's stock symbol is BVXV. Lastest price : 3.1000. Total volume :100.86k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.biondvax.com

  • Host name: 198.49.23.145
  • IP address: 198.49.23.145
  • Location: New York United States
  • Latitude: 40.7157
  • Longitude: -74
  • Metro Code: 501
  • Timezone: America/New_York
  • Postal: 10013

Loading ...
Loading ...


More informations about "Biondvax" on Search Engine

BiondVax Pharmaceuticals Ltd

Biondvax.com BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on development and manufacturing of products for the prevention of infectious diseases.

BiondVax Pharmaceuticals Ltd

Biondvax.com BiondVax Press Releases — BiondVax Pharmaceuticals Ltd

BiondVax Pharmaceuticals Ltd

Biondvax.com Company Profile. BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a …

BiondVax Pharmaceuticals Ltd

Biondvax.com BiondVax's Financial Reports and Results Please select from the links below to the …

BiondVax Pharmaceuticals Ltd

Biondvax.com BiondVax Management Board of Directors Scientific Advisory Board Current Page: …

BiondVax Pharmaceuticals Ltd

Biondvax.com BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company …

BiondVax Pharmaceuticals Ltd

Biondvax.com BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company …

BiondVax Pharmaceuticals Ltd. (BVXV) Stock Price, News

Finance.yahoo.com BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious...

BiondVax - Wikipedia

En.wikipedia.org BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company developing a universal influenza vaccine called M-001. BiondVax is a publicly traded company, listed on the NASDAQ. The vaccine technology was invented in the 1990s at the Weizmann Institute of Science in the laboratory of Ruth Arnon, and was licensed to BiondVax in 2003.

BiondVax Pharmaceuticals Ltd. (BVXV) Latest Stock News

Finance.yahoo.com BiondVax Pharmaceuticals is developing a potential stand-alone universal flu vaccine, M-001. In a pivotal clinical trial, the company tested M-001's safety and efficacy at reducing flu illness and...

BiondVax Announces Appointment of Amir Reichman as New CEO

Nasdaq.com Jan 21, 2021 · BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on development and manufacturing of products for the prevention of infectious diseases.

Why BiondVax Pharmaceuticals Stock Imploded Today | The

Fool.com Oct 24, 2020 · BiondVax Pharmaceuticals is developing a potential stand-alone universal flu vaccine, M-001. In a pivotal clinical trial, the company tested M-001's safety and efficacy at reducing flu illness and...

BVXV Stock Price | BiondVax Pharmaceuticals Ltd. ADR Stock

Marketwatch.com Mar 29, 2021 · BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It …

BiondVax Announces Topline Results from Phase 3 Clinical

Prnewswire.com Oct 23, 2020 · BiondVax (NASDAQ: BVXV) is a biopharmaceutical company that has been developing M-001, a novel flu vaccine candidate. The vaccine candidate was …

Why BiondVax Pharmaceuticals Stock Imploded Today

Msn.com Oct 23, 2020 · BiondVax Pharmaceuticals is developing a potential stand-alone universal flu vaccine, M-001. In a pivotal clinical trial, the company tested M-001's safety and efficacy at reducing flu illness and...

BiondVax Pharmaceuticals: A Small, Undervalued Biotech

Seekingalpha.com Biondvax is a biotech company in what appears to be a binary situation. In the unlikely event that the phase 3 study should fail, there are no other products in the pipeline to replace it, at...

BiondVax Announces Third Quarter 2020 Financial Results

Wfmz.com BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing …

BiondVax Announces Appointment of Amir Reichman as New CEO

Wfmz.com JERUSALEM, Jan. 21, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for …

@biondvax | Twitter

Twitter.com The latest tweets from @biondvax

Universal Flu Vaccines Yield Second Clinical Failure This Year

Labiotech.eu Oct 29, 2020 · Last week proved a major setback for the Israeli biotech BiondVax. The company’s vaccine — designed to protect against multiple strains of flu — failed in phase III. This was BiondVax’s only clinical candidate and investors reacted poorly, sending the stock into free fall.

Biondvax Pharmaceuticals Ltd - ADR (BVXV : NASDAQ) Stock

Google.com BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company developing a universal influenza vaccine called M-001. BiondVax is a publicly traded company, listed on the NASDAQ. The vaccine...

BiondVax Pharmaceuticals Ltd. American Depositary Shares

Nasdaq.com BiondVax Pharmaceuticals Ltd. American Depositary Shares (BVXV)

Letter from BiondVax's New CEO to Shareholders | Markets

Markets.businessinsider.com Mar 23, 2021 · BiondVax's mission is to help build a healthier and happier world by developing, manufacturing and ultimately commercializing products for the prevention and treatment of …

BiondVax Announces Appointment of Amir Reichman as New CEO

Morningstar.com Jan 21, 2021 · BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on development and manufacturing of products for the prevention of infectious diseases. The Company had been ...

BiondVax Pharmaceuticals Ltd ADR (BVXV) Quote - XNAS

Morningstar.com BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to …

Letter from BiondVax's New CEO to Shareholders

Prnewswire.com Mar 23, 2021 · BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for …

BiondVax, Universal flu | FiercePharma

Fiercepharma.com Sep 29, 2020 · BiondVax is working on a flu vaccine that could protect over several years.

BiondVax - Crunchbase Company Profile & Funding

Crunchbase.com BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDX) located in the Weizmann Science Park in Ness-Ziona (Israel), is dedicated to the development of a novel Universal Influenza Vaccine. BiondVax's Universal Flu Vaccine is based on research carried out over a period of 20 years by Weizmann Institute Professor Ruth Arnon, who heads

BiondVax edges closer to elusive universal flu vaccine

Jpost.com Mar 19, 2019 · BiondVax edges closer to elusive universal flu vaccine Every year, seasonal influenza causes about 290,000 to 650,000 respiratory deaths, and a …

BVXV: BiondVax Pharmaceuticals Ltd - Stock Price, Quote

Cnbc.com BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine.

BVXV Stock News - Fidelity

Eresearch.fidelity.com Apr 13, 2021 · BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares. PR Newswire – 7:57 AM ET 01/29/2021. JERUSALEM, Jan. 29, 2021 BiondVax Pharmaceuticals Ltd. ( BVXV ), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and ...

Biondvax Pharmaceuticals Ltd - ADR BVXV - Quotes

Money.usnews.com BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It works on M-001, a ...

Is Biondvax Pharmaceuticals Ltd - ADR (BVXV) a Stock to

Investorsobserver.com Feb 08, 2021 · BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus …

BVXV | Stock Snapshot - Fidelity

Eresearch.fidelity.com Apr 12, 2021 · BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of ...

BiondVax - Home | Facebook

Facebook.com Jerusalem, Israel – August 13, 2020 – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M‑001 universal influenza vaccine candidate, today announced that the Annual General Meeting of Shareholders of the Company will be held on September 2, 2020 in Tel Aviv,...

BiondVax Pharmaceuticals Ltd. (BVXV) Stock Price Today

Seekingalpha.com BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel.

BVXV - Stock quote for BIONDVAX PHARMACEUTICALS LTD - …

Msn.com Apr 08, 2021 · Letter from BiondVax's New CEO to Shareholders. WFMZ-TV 3/23/2021. Biondvax Pharmaceuticals Ltd (spons. ADRs) Stock , BVXV. Business Insider 4/1/2021.

BVXV | BiondVax Pharmaceuticals Ltd. ADR Stock Price

Wsj.com PROFILE ( BVXV) BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It …

Do Traders View Biondvax Pharmaceuticals Ltd - ADR (BVXV)

Investorsobserver.com Jan 13, 2021 · BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus …

BiondVax Gets OK to Build Plant in Israel (BVXV)

Investopedia.com Jun 25, 2019 · BiondVax Pharmaceuticals Ltd. secured a grant from the Israel Investment Center, a unit of the Government of Israel's Ministry of Economy and Industry, to build a manufacturing facility for the ...

BVXV Stock Price, BiondVax Pharmaceuticals Stock Quotes

Benzinga.com Jan 01, 2019 · BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine.

BVXV | BiondVax Pharmaceuticals Ltd. ADR Company Profile

Wsj.com BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases.

BVXV - BiondVax Pharmaceuticals Ltd Stock quote - CNNMoney.com

Money.cnn.com Find real-time BVXV - BiondVax Pharmaceuticals Ltd stock quotes, company profile, news and forecasts from CNN Business.

BiondVax - Home | Facebook

Facebook.com BiondVax, Jerusalem, Israel. 343 likes · 99 talking about this · 15 were here. BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and...

Biondvax plunges on failed universal flu vaccine trial

En.globes.co.il Oct 25, 2020 · Biondvax's flu vaccine was based on development by Prof. Ruth Arnon of the Weizmann Institute of Science, who also co-developed Teva's blockbuster multiple sclerosis treatment Copaxone. Full disclosure: Marius Nacht is the former partner of Anat …

Universal Flu Vaccine May Offer 1-Shot Protection

Webmd.com Jan 18, 2019 · BiondVax’s M-001 vaccine includes nine parts of the virus that don’t change. These viral parts contain segments common to 40,000 known flu strains, Ben-Yedidia says.

BiondVax Announces Closing of $12.1 Million Follow-on

Benzinga.com Feb 03, 2021 · BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) is a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for …

BVXV Stock Price Quote & News - BiondVax Pharmaceuticals

Robinhood.com BiondVax Pharmaceuticals Ltd. American Depositary Shares, also called BiondVax Pharmaceuticals, is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases.

BVXV | BiondVax Pharmaceuticals Ltd. ADR Profile | MarketWatch

Marketwatch.com Feb 08, 2021 · BiondVax Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases. It …

BiondVax Pharmaceuticals Ltd. | LinkedIn

Linkedin.com BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company that has been developing M-001, a novel flu vaccine candidate. The vaccine candidate was designed to provide multi ...

BiondVax Security Report and Data Breaches

Upguard.com BiondVax. This is a preliminary report on BiondVax’s security posture. If you want in-depth, always up-to-date reports on BiondVax and millions of other companies, consider booking a demo with us. UpGuard is the new standard in third-party risk management and attack surface management.

BiondVax’s universal flu vaccine combats all influenza

Israel21c.org Jan 21, 2014 · BiondVax’s vaccine was designed to contain small pieces of the flu virus that do not change as they are required for the virus’s lifecycle. These small pieces are enough to teach the human immune system to recognize all flu strains, so that the body quickly stops the virus from causing illness.

www.sec.gov

Sec.gov BiondVax Pharmaceuticals Ltd. (hereinafter, the “Registrant”, the “Company”, or “BiondVax”) hereby furnishes the following documents in connection with an Extraordinary Meeting of Shareholders scheduled for April 6, 2021 at 4:00 p.m. Israel time at the offices of Gross & Co.,One Azrieli Center, Round Tower, Tel Aviv 6701101, Israel:

BiondVax Pharmaceuticals Ltd. ADR Stock Price (BVXV)

Barrons.com Mar 16, 2021 · View today's stock price, news and analysis for BiondVax Pharmaceuticals Ltd. ADR (BVXV). Barron's also provides information on historical …